Application of cembratrienol in preparation of medicine for preventing and / or treating psoriasis

Abstract

The invention relates to application of cembratrienol in preparation of a medicine for preventing and / or treating psoriasis, and belongs to the technical field of biological medicine. The invention provides an application of cembratrienol in preparation of a medicine for preventing / or treating psoriasis. Researches find that cembratrienol can significantly inhibit secretion of inflammatory factors in a psoriasis-like cell model induced by M5; moreover, research finds that cembratrienol can significantly improve the skin lesion condition of an imiquimod-induced psoriasis mouse model, improve the weight loss degree of the psoriasis mouse model, relieve the pruritus condition of the psoriasis mouse model, improve the skin inflammation of the psoriasis mouse model, repair the skin barrier of the psoriasis mouse model, and improve the curative effect of the psoriasis mouse model. The body immune response of the psoriasis mouse model is reduced. Therefore, cembratrienol has a great application prospect in preparation of the medicine for preventing / treating psoriasis.

Description

Technical Field

[0001] The invention relates to application of cephalexin in preparing medicine for preventing and / or treating psoriasis, belonging to the technical field of biomedicine. Background Art

[0002] Psoriasis, commonly known as psoriasis, is a chronic inflammatory skin disease stimulated by environmental factors, controlled by polygenic inheritance, and mediated by immunity. The most important clinical type of psoriasis is psoriasis vulgaris, which is mainly skin damage. Its typical clinical manifestations are clearly bordered erythema covered with scales, which can accumulate in any part of the body. Although the pathogenesis of psoriasis is not fully understood, autoimmune factors and heredity are the main risk factors for psoriasis. In the immune pathogenesis of psoriasis, proinflammatory cytokines synergistically stimulate keratinocytes to produce many inflammatory factors, thereby attracting and activating T17 cells and neutrophils, which continue to produce cytokines, stimulating keratinocytes to continue to proliferate and produce inflammatory factors.

[0003] The World Health Organization (WHO) defines psoriasis as an "incurable chronic, non-communicable, painful, disfiguring and disabling disease". Most patients with psoriasis will suffer some impairment to their quality of life due to the disease, which will have a substantial negative impact on their psychosocial health. For example, patients with psoriasis lesions involving functionally critical areas such as the face, palms, soles and genitals have a significant psychological impact. Studies have shown that compared with the general population, patients with psoriasis are more likely to be depressed (depression rates as high as 20%) and show suicidal ideation that extends to suicidal behavior.

[0004] At present, the treatment methods of psoriasis mainly include systemic treatment (for example, oral immunosuppressants, biological agents and antibiotics for intervention), topical drug treatment (for example, topical moisturizers, immunosuppressants, vitamin D3 derivatives, calcineurin inhibitors and retinoic acid preparations for intervention), physical therapy (for example, UVA phototherapy combined with psoralen intervention and UVB phototherapy intervention) and comprehensive Chinese medicine therapy (for example, oral Chinese medicine compound preparation intervention, acupuncture intervention, external application of Chinese medicine ointment intervention and medicinal bath intervention). Although the intervention methods are diverse, they can only have short-term effects, and as the number of recurrences or severity of the disease increases, the previous efficacy will have a marginal diminishing effect. In addition, these intervention methods still have many practical problems. For example, biological agents are currently only for patients with moderate and severe psoriasis, and they are expensive. Psoriasis cannot be cured and requires long-term medication, which puts too much burden on patients; immunosuppressants such as glucocorticoids have obvious side effects, and long-term use is prone to dependence. Considering that most psoriasis patients have mild symptoms and their skin damage accounts for less than 3% of the body surface area, topical medications can be used alone. Therefore, there is an urgent need to find more topical medications that are low-cost, have few side effects, and are effective in inhibiting inflammation, relieving itching and repairing the skin barrier as daily skin care drugs for psoriasis.

[0005] β-Cembrenediol (β-CBD, CAS: 57605-81-9) is an important aroma precursor in tobacco. Studies have shown that β-Cembrenediol is not harmful to the human body, but also has multiple biological activities such as anti-tumor, neuroprotection, antibacterial and insecticidal, and is highly safe. In addition, β-Cembrenediol is easy to obtain and inexpensive. At present, there are no reports on the use of β-Cembrenediol to prevent / or treat psoriasis. Summary of the invention

[0006] In order to solve the above problems, the present invention provides the use of cephalexin in the preparation of a drug for preventing and / or treating psoriasis.

[0007] In one embodiment of the present invention, the prevention and / or treatment of psoriasis includes inhibiting the secretion of inflammatory factors caused by psoriasis, improving skin damage caused by psoriasis, improving weight loss caused by psoriasis, relieving skin itching caused by psoriasis, relieving skin inflammation caused by psoriasis, repairing skin barrier damage caused by psoriasis and / or reducing the body's immune response caused by psoriasis.

[0008] In one embodiment of the present invention, the ingredients of the drug include active components and pharmaceutical excipients; the active component includes cephalexin.

[0009] In one embodiment of the present invention, the active ingredient is cephalexin.

[0010] In one embodiment of the present invention, the pharmaceutical excipients include surfactants, excipients, stabilizers, suspending agents, isotonic agents, preservatives, fillers, disintegrants, antioxidants, emulsifiers, coating agents, adhesives, lubricants and / or flavoring agents.

[0011] In one embodiment of the present invention, the dosage form of the drug is a liniment; the liniment includes a solution-type liniment, a suspension-type liniment and / or an emulsion-type liniment.

[0012] The present invention also provides a drug for preventing and / or treating psoriasis, wherein the drug contains an active component; the active component includes cephalexin.

[0013] In one embodiment of the present invention, the prevention and / or treatment of psoriasis includes inhibiting the secretion of inflammatory factors caused by psoriasis, improving skin damage caused by psoriasis, improving weight loss caused by psoriasis, relieving skin itching caused by psoriasis, relieving skin inflammation caused by psoriasis, repairing skin barrier damage caused by psoriasis and / or reducing the body's immune response caused by psoriasis.

[0014] In one embodiment of the present invention, the active ingredient is cephalexin.

[0015] In one embodiment of the present invention, the composition of the drug further includes pharmaceutical excipients.

[0016] In one embodiment of the present invention, the pharmaceutical excipients include surfactants, excipients, stabilizers, suspending agents, isotonic agents, preservatives, fillers, disintegrants, antioxidants, emulsifiers, coating agents, adhesives, lubricants and / or flavoring agents.

[0017] In one embodiment of the present invention, the dosage form of the drug is a liniment; the liniment includes a solution-type liniment, a suspension-type liniment and / or an emulsion-type liniment.

[0018] The technical solution of the present invention has the following advantages:

[0019] The present invention provides the use of cephalexin in preparing a medicine for preventing and / or treating psoriasis. The study found that cephalosporin can significantly inhibit the secretion of inflammatory factors (including IL-1β and IL-6) in the psoriasis-like cell model induced by M5 (IL-1α, IL-17, IL-22, oncostatin M and tumor necrosis factor-α); and the study found that cephalosporin can significantly improve the skin lesions of the psoriasis mouse model induced by imiquimod (IMQ) (including improving the back skin symptoms such as scabs, thickening of keratin, wrinkles and redness, and reducing the area and severity index of psoriasis lesions), improve the weight loss of the psoriasis mouse model, relieve the itching of the psoriasis mouse model (including reducing the number of scratching and reducing the expression level of KLK7 protein in skin tissue), improve the skin inflammation of the psoriasis mouse model, repair the skin barrier of the psoriasis mouse model (including increasing the expression level of FLG protein in skin tissue), and reduce the body's immune response of the psoriasis mouse model (including reducing the spleen volume and weight). Therefore, cephalexin has great application prospects in the preparation of drugs for preventing and / or treating psoriasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 :Effects of different concentrations of cephalatrienol on the viability of HaCat cells.

[0021] Figure 2 : The expression levels of IL-1β in different groups of cells.

[0022] Figure 3 : The expression levels of IL-6 in different groups of cells.

[0023] Figure 4 : Typical manifestations of the back skin of mice in different groups from 0 to 7 days.

[0024] Figure 5 : Body weight changes of mice in different groups from day 0 to day 7.

[0025] Figure 6 : The scratching situation of mice in different groups on the third day.

[0026] Figure 7 : The scratching situation of mice in different groups on the 6th day.

[0027] Figure 8 : PASI scores of mice in different groups.

[0028] Fig. 9 : Epidermal thickness of mice in different groups (H&E pathological detection).

[0029] Fig.10 : Expression levels of FLG protein and KLK7 protein in skin tissues of different groups of mice (immunohistochemistry).

[0030] Fig.11 : Spleen sizes of mice in different groups.

[0031] Fig.12 : Spleen weights of mice in different groups.

[0032] Figures 1 to 12 Medium, *P<0.05. DETAILED DESCRIPTION

[0033] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.

[0034] If no specific experimental steps or conditions are specified in the following examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be purchased commercially.

[0035] Experimental Example 1: Effects of Cebutrienol on Psoriasis-like Cell Model

[0036] The experimental process is as follows:

[0037] 1. Determination of drug concentration

[0038] HaCat cells (purchased from Xinrun Biotechnology, catalog number IH1006) were cultured at 5×10 3 After the inoculation amount was inoculated into a 96-well plate with 100 μL of DMEM medium (purchased from Gibco) containing 10% (v / v) fetal bovine serum, 100 U / mL penicillin and 100 U / mL streptomycin per well, the plate was cultured in a cell culture incubator at 37°C and 5% (v / v) CO2 for 24 hours. After the culture, cephalotrienol (purchased from Shanghai Sai Ke Rui Biotechnology Co., Ltd.) was first added to the 96-well plate until the concentration of cephalotrienol was 1, 10, 25, 50, 75, and 100 pg / mL, respectively, and incubated in a cell culture incubator at 37°C and 5% (v / v) CO2 for 24 hours, and then CCK-8 (purchased from MCE) was added to the 96-well plate at an amount of 10 μL per well, and incubated in a cell culture incubator at 37°C and 5% (v / v) CO2 for 1 hour. After the incubation, the absorbance of each well at 450 nm was measured using an ELISA reader, and the cell viability of each group of cells was calculated according to the formula: cell viability = [(As-Ab) / (Ac-Ab)] × 100%. The experimental results are shown in Figure 1; Where As is the absorbance of the experimental well (containing cells, culture medium, CCK-8 solution and drug solution), Ab is the absorbance of the control well (containing cells, culture medium, CCK-8 solution but not containing drugs), and Ac is the absorbance of the blank well (containing culture medium and CCK-8 solution but not containing cells or drugs).

[0039] Depend on Figure 1 It can be seen that within the concentration range below 100 pg / mL, cephalothinol has no significant effect on the viability of HaCat cells. A drug concentration of 50 pg / mL was selected for subsequent experiments.

[0040] 2. Effects of cepatrienol on psoriasis-like cell model

[0041] The experiment was divided into three groups: blank group, M5 group, and M5+cephalatrienol group (M5+β group). In the M5 group, HaCat cells were cultured at 2×10 5 After the inoculation amount of 100 cells / well was inoculated into a 6-well plate with 2 mL of DMEM medium added to each well, 10 μg / L IL-1α (purchased from PEPROTech, model 200-01A), 10 μg / L IL-17 (purchased from PEPROTech, model 200-17), 10 μg / L IL-22 (purchased from PEPROTech, model 200-22), 10 μg / L tumor necrosis factor-α (TNF-α, purchased from PEPROTech, model 300-01A) and 10 μg / L oncostatin M (Oncostatin M, purchased from PEPROTech, model 300-10H) were added to the DMEM medium to stimulate HaCat cells, and cultured in a cell culture incubator at 37° C. and 5% (v / v) CO2 for 26 hours to induce the psoriasis keratinocyte model in vitro;

[0042] In the blank group, no substance was added to the DMEM medium;

[0043] M5+cetabtrienol group: HaCat cells were plated at 2×10 5After inoculating the cells in a 6-well plate with 2 mL of DMEM medium in each well, 10 μg / L IL-1α (purchased from PEPROTech, model 200-01A), 10 μg / L IL-17 (purchased from PEPROTech, model 200-17), 10 μg / L IL-22 (purchased from PEPROTech, model 200-22), 10 μg / L tumor necrosis factor-α (TNF-α, purchased from PEPROTech, model 300-01A) and 10 μg / L oncostatin M (Oncostatin M, purchased from PEPROTech, model 300-10H) were added to the DMEM medium, and the cells were cultured in a cell culture incubator at 37°C and 5% (v / v) CO2 for 2 hours. Then, 50 pg / mL of cephalothin were added to the DMEM medium, and the cells were cultured in a cell culture incubator at 37°C and 5% (v / v) CO2 for 24 hours.

[0044] After the culture was completed, the three groups of cells were collected and the expression levels of IL-1β (ELISA kit for detecting IL-1β in supernatant was purchased from abcam, model ab214025) and IL-6 (ELISA kit for detecting IL-6 in supernatant was purchased from abcam, model ab178013) in the cell culture supernatant were detected by ELISA kits. The detection results are shown in Figure 2-3 .

[0045] Figure 2-3 The experimental results showed that HaCaT cells secreted less IL-1β and IL-6 by themselves, and 26 hours after adding M5, the secretion of IL-1β and IL-6 increased significantly, indicating that an inflammatory response had occurred; 24 hours after adding cephalotrinol to the M5 model, the secretion of IL-1β and IL-6 decreased, suggesting that the inflammatory response was suppressed. These findings provide an experimental basis for the potential application of cephalotrinol in the treatment of psoriasis.

[0046] Experimental Example 2: Effects of Cebutrienol on Psoriasis Mouse Model

[0047] The experimental process is as follows:

[0048] The male BALB / c mice (6-8 weeks old, 18-22 g) used in the experiment were purchased from Beijing Weitong Lihua Company. Housing conditions: constant temperature of 24±2℃, humidity of 55%±15%, light / dark cycle of 12 hours, free access to water and food. The use of all animals was approved by the Institutional Animal Care and Use Committee (IACUC). After the mice adapted to the laboratory for 1 week, 3×3 cm of hair was shaved on the back. The experiment started 24 hours after shaving. The experiment was divided into 6 groups, namely normal group, IMQ group, IMQ+cepharienol low concentration group (IMQ+β low), IMQ+cepharienol medium concentration group (IMQ+β medium), IMQ+cepharienol high concentration group (IMQ+β high) and methotrexate group (MTX group). Among them, the mice in the normal group did not undergo any operation;

[0049] The IMQ group was treated with Aldara cream (Sichuan Mingxin Pharmaceutical Co., Ltd., China) containing 5% (w / v, g / 100 mL) imiquimod (IMQ) applied to the shaved area of ​​the mice once a day, with a dose of 0.0625 g each time, for 7 consecutive days (the day before application was recorded as 0 day) to establish a psoriasis mouse model.

[0050] The IMQ+low-concentration cephalatrienol group was based on the IMQ group. Starting from the first day of application, cephalatrienol was applied to the shaved area of ​​the mice 2 hours after applying Aldara cream containing 5% imiquimod. The application was performed once a day, with a dose of 1 mg / kg each time (cephalatrienol was prepared into 50 μL aqueous solution for application), and the application lasted for 7 days (the day before application was recorded as 0 day) to treat the psoriasis mouse model.

[0051] The IMQ+medium concentration of cephalatrienol group was based on the IMQ group. Starting from the first day of application, cephalatrienol was applied to the shaved area of ​​the mice 2 hours after applying Aldara cream containing 5% imiquimod. The application was performed once a day, with a dose of 5 mg / kg each time (cephalatrienol was prepared into 50 μL aqueous solution for application), and the application lasted for 7 days (the day before application was recorded as 0 day) to treat the psoriasis mouse model.

[0052] The IMQ+high-concentration cephalatrienol group was based on the IMQ group. Starting from the first day of application, cephalatrienol was applied to the shaved area of ​​the mice 2 hours after applying Aldara cream containing 5% imiquimod. The application was performed once a day, with a dose of 10 mg / kg each time (cephalatrienol was prepared into 50 μL aqueous solution for application), and the application lasted for 7 days (the day before application was recorded as 0 day) to treat the psoriasis mouse model.

[0053] The methotrexate group was treated with intraperitoneal injection of methotrexate 2 hours after application of Aldara cream containing 5% imiquimod, based on the IMQ group, once a day, with each injection dose of 1 mg / kg (methotrexate was dissolved in 100 μL of saline and injected) for 7 consecutive days (the day before injection was recorded as 0d) to treat the psoriasis mouse model.

[0054] During the experiment, mice were photographed and weighed every day. The photographic results are shown in Figure 4 , weighing results see Figure 5 On the 3rd and 6th days of the experiment, the itch of mice was studied, and the number of scratching times of each mouse in each group within 30 minutes was counted (the final result was the mean of each group of mice). The statistical results are shown in Figure 6-7 . The Psoriasis Area and Severity Index (PASI) measures the severity of clinical inflammation on the back (see the literature: M.Na Takuathung, A.Wongnoppavich, A.Panthong, P.Khonsung, N.Chiranthanut, N.Soonthornchareonnon, and S.Sireeratawong: "Antipsoriatic Effects of Wannachawee Recipe on Imiquimod-Induced Psoriasis-Like Dermatitis in BALB / cMice." Evid.-Based Complement.Altern.Med.ECAM.vol.2018,pp.7931031,2018.). The erythema, scaling, and thickness scratches of the mouse skin were scored separately. Each item was scored on a 4-point scale (0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = extremely severe). The individual scores were added together to obtain a total score of up to 9 points. The scoring results are as follows: Figure 8 On the 8th day of the experiment, the mice were killed by dislocation of the neck, and the mouse skin was fixed with formalin, embedded in paraffin, sliced ​​(thickness 4 μm), stained with hematoxylin and eosin (H&E), and histopathological examination was performed. The examination results are shown in Fig. 9 .

[0055] Filaggrin (FLG) has a protective function in maintaining the skin barrier. Kallikrein 7 (KLK7) is a serine protease that is involved in the proteolysis of extracellular corneal junction components, leading to desquamation. It has been shown that increased levels of KLK7 induce spontaneous pruritus in mice. To further study the protective function of cebutrienol on the skin barrier, immunohistochemistry of FLG and KLK7 proteins was performed on mouse skin tissue on day 8 of the experiment. The immunohistochemistry results are shown in Fig.10Among them, the immunohistochemical method is as follows:

[0056] Mouse skin was fixed with formalin, embedded in paraffin, and sliced ​​(thickness 4 μm). The slides were placed in a 65°C oven and heated for 1 hour until dewaxed and hydrated, and then immersed in EDTA repair solution (purchased from Thermo). The slides immersed in EDTA repair solution were first treated with a microwave oven at low heat for 5 minutes, then cooled to room temperature (25°C), and finally treated with a microwave oven at high heat for 5 minutes. After the slides were taken out of the EDTA repair solution, they were immersed in 3% (w / v, g / 100mL) hydrogen peroxide at room temperature (25°C) for 5 minutes to eliminate endogenous peroxidase activity. After the immersion, the slides were rinsed three times with PBS buffer (pH 7.4, concentration 0.01M, Gibco), each for 2 minutes. After the rinsing, the slides were immersed in normal sheep serum (5% working solution, purchased from Zhongshan Jinqiao, model ZLI-9022) for blocking at room temperature (25°C) for 10 minutes. After the soaking, the slides were incubated with different primary antibodies at 37°C for 1 hour, where the primary antibodies were: FLG protein (FLG protein was purchased from Shanghai Qincheng Biotechnology Co., Ltd., model QC103Hu01, diluted 100 times with primary antibody diluent, and the primary antibody diluent was purchased from Beyotime, model P0103) and KLK7 protein (KLK7 protein was purchased from abcam, model ab254258, and diluted 200 times with primary antibody diluent). After the incubation, the slides were washed three times with PBS buffer, each time for 2 minutes. After the rinsing, the slides were first incubated with biotin-conjugated secondary antibodies (biotin-conjugated secondary antibodies were purchased from Beyotime, model A0279, and used after diluting 5000 times with secondary antibody solution, and the secondary antibody diluent was purchased from Beyotime, model P0267) at 37°C for 30 minutes. After the incubation, 50 μL of DAB working solution (DAB working solution purchased from Bio-Tech, model P0202) was added to the slide to cover the skin tissue, and the staining was observed under a microscope. After the staining was completed, the color reaction was stopped by washing with purified water. After the color reaction was stopped, the image was taken using a Zeiss optical fluorescence inverted microscope Primovert.

[0057] The spleen is a very important immune organ in the body. The spleen is usually studied to infer the body's immune response. In order to further study the effect of cebutrienol on the body's immune response, mice were killed by dislocation of the neck on the 8th day of the experiment, and the spleen of the mice was removed for volume and weight observation. The results are shown in Figure 11-12 .

[0058] Figure 4The experimental results showed that continuous application of IMQ on the back skin of mice caused scabs, thickening of the keratin, wrinkles and redness. After administration of different concentrations of cerebrum trienol, the symptoms on the back of mice were significantly alleviated, while the degree of alleviation of the back symptoms of mice in the MTX group was far less than that in the IMQ + cerebrum trienol low concentration group, IMQ + cerebrum trienol medium concentration group and IMQ + cerebrum trienol high concentration group.

[0059] Figure 5 The experimental results showed that the weight of mice in the normal group hardly changed, indicating that the mice were basically mature and stable; but after being given IMQ, the weight of mice decreased significantly from the first day, reaching the lowest value on the fourth day, and then the weight did not recover significantly, indicating that IMQ caused serious damage to the mice's bodies; after giving IMQ mice different concentrations of cephalotrienol, the weight of mice was alleviated compared with IMQ mice not given cephalotrienol. By the fourth day, the weight of mice reached the lowest value, and then the weight recovered significantly, indicating that after being given cephalotrienol, the physical condition of mice was significantly improved; the weight loss of mice in the MTX group was alleviated, but not as good as the cephalotrienol group III.

[0060] Figure 6-7 The experimental results showed that the number of scratching times of mice in the IMQ group was significantly higher than that of mice in other groups, indicating that administration of cephalexin can effectively inhibit the number of scratching times of mice.

[0061] Figure 8 The PASI scores of six groups of mice were compared, including the blank group, IMQ group, IMQ + low-concentration cedarwood group, IMQ + medium-concentration cedarwood group, IMQ + high-concentration cedarwood group, and IMQ + MTX group. The area and severity of psoriasis lesions in the IMQ group were more serious than those in the other five groups, and the IMQ + MTX group was more serious than the IMQ + low-concentration cedarwood group, IMQ + medium-concentration cedarwood group, and IMQ + high-concentration cedarwood group.

[0062] Fig. 9 The epidermal thickness of five groups of mice, including the blank group, IMQ group, IMQ + low-concentration cedarwood group, IMQ + medium-concentration cedarwood group and IMQ + high-concentration cedarwood group, was compared. The experimental results showed that the epidermal thickness of the normal group of mice was very thin, which was a normal phenomenon; after administration of IMQ, the epidermal spinous layer of the mice was significantly thickened, and the spinous processes were significantly enlarged and lengthened, which was consistent with the characteristics of psoriasis skin pathology; compared with the IMQ group, the epidermal spinous layer of the mice in the low-concentration IMQ + cedarwood group, the medium-concentration IMQ + cedarwood group and the high-concentration IMQ + cedarwood group were significantly thinner, and the spinous processes were shortened or even disappeared. It can be seen that administration of cedarwood can effectively relieve the local inflammation caused by psoriasis.

[0063] Fig.10The experimental results showed that the skin barrier function of the normal group of mice was sound and there was no itching, so immunohistochemistry showed that FLG expression was the highest and KLK7 expression was the lowest; the skin barrier of the IMQ mice was damaged and they kept scratching, and immunohistochemistry showed that FLG expression was the lowest and KLK7 expression was the highest; compared with the IMQ group, the skin barrier of the three groups of mice in the IMQ+low-concentration cedarwood group, IMQ+medium-concentration cedarwood group and IMQ+high-concentration cedarwood group was restored and the itching was alleviated, and immunohistochemistry showed that FLG expression was higher than that in the IMQ group, and KLK7 expression was lower than that in the IMQ group.

[0064] Figure 11-12 The experimental results showed that the spleen of IMQ mice was significantly enlarged. After administration of cephalotrienol, the spleen volume and weight decreased. It is speculated that cephalotrienol reduced the body's immune response.

[0065] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. Use of cephalexin in the preparation of drugs for preventing and / or treating psoriasis.

2. The use according to claim 1, characterized in that The prevention and / or treatment of psoriasis includes inhibiting the secretion of inflammatory factors caused by psoriasis, improving skin damage caused by psoriasis, improving weight loss caused by psoriasis, relieving skin itching caused by psoriasis, relieving skin inflammation caused by psoriasis, repairing skin barrier damage caused by psoriasis and / or alleviating the body's immune response caused by psoriasis.

3. The use according to claim 1 or 2, characterized in that: The ingredients of the medicine include active components and pharmaceutical excipients; the active component includes cephalexin.

4. The use according to claim 3, characterized in that The pharmaceutical excipients include surfactants, excipients, stabilizers, suspending agents, isotonic agents, preservatives, fillers, disintegrants, antioxidants, emulsifiers, coating agents, adhesives, lubricants and / or flavoring agents.

5. The use according to any one of claims 1 to 4, characterized in that: The dosage form of the drug is an ointment; the ointment includes a solution-type ointment, a suspension-type ointment and / or an emulsion-type ointment.

6. A drug for preventing and / or treating psoriasis, characterized in that: The medicine contains an active ingredient; the active ingredient comprises cephalexin.

7. The drug according to claim 6, characterized in that The prevention and / or treatment of psoriasis includes inhibiting the secretion of inflammatory factors caused by psoriasis, improving skin damage caused by psoriasis, improving weight loss caused by psoriasis, relieving skin itching caused by psoriasis, relieving skin inflammation caused by psoriasis, repairing skin barrier damage caused by psoriasis and / or alleviating the body's immune response caused by psoriasis.

8. The drug according to claim 6 or 7, characterized in that The ingredients of the medicine also include pharmaceutical excipients.

9. The drug according to claim 8, characterized in that The pharmaceutical excipients include surfactants, excipients, stabilizers, suspending agents, isotonic agents, preservatives, fillers, disintegrants, antioxidants, emulsifiers, coating agents, adhesives, lubricants and / or flavoring agents.

10. The drug according to any one of claims 6 to 9, characterized in that The dosage form of the drug is an ointment; the ointment includes a solution-type ointment, a suspension-type ointment and / or an emulsion-type ointment.

Images